Found "AI": 1,093 results
11th HTAsiaLink Annual Conference 2023 Awards Winners
The HTAsiaLink Annual Conference for this year happened on 4 – 7 September, hosted by the Malaysia Health Technology Assessment Section (MaHTAS) under the Ministry of Health, Malaysia.
Researchers from HITAP participated in the conference and presented their research projects thr
10th HTAsiaLink Annual Conference 2022 Awards Winners
On 2 Dec 2022, our outstanding presenters received big achievements by winning amazing awards at the 10th HTAsiaLink Annual Conference 2022 which virtually held on 30 November – 2 December 2022. The winners are as listed below:Best Oral PresentationsTrack: Economic EvaluationSecond Prize: Chittawan
Preventing end-stage renal disease in Thai newly-diagnosed severe lupus nephritis patients: cost-effectiveness of alternative drug regimens (research for development of the health benefit package under the Universal Coverage scheme)
The purpose of this study is to compare the cost-utility of each treatment option available today in order to determine the most cost-effective treatment compared with standard treatment in the social perspective. Research methodology is an economic evaluation by using the markov model to compare the cost and utility of treatment options of new pat
Views of Health Professionals on Herbal Medicine and Policy for Promotion of Herbal Medicine Use in Healthcare Settings(in Thai Language)
Thailand has promoted the use of herbal medicine for many years, but the value of herbal medicine in public health facilities does not meet the established target. The survey of health practitioners towards herbal medicine and the policy in promotion of the use of herbal medicine in health practitioners gives us information reinforcing and resistan
Evaluation of the National Essential Drug List Category E2 2008 (in Thai language)
The objective of this study is to promote the rational drug use of Thailand. E List, clause 2 for specific patients is added in the National List of Essential Medicines, 2551 B.E. Ten medicines, which require knowledge, specialization in disease or advanced technology, are included in the list. However, it is likely that the prescription of these m
Development of population-based screening package in Thailand
This project aims to propose an additional and unified screening package for the Thai population, building upon that offered already by the UC, which will be useful to allocate resources more efficiently and reduce the inequity gap among the three insurance scheme beneficiary groups. 1. To prioritize diseases for screening based on availab
Effectiveness of home visit: A systematic review of systematic reviews
This study aims to explore effectiveness of home visit on clinical, economic, and humanistic outcomes employing systematic review. Home visits for all diseases and within all patient groups are included, provided that inclusion criteria are met. Results are expected to be useful for (1) developing guidelines for home visit for health professionals,
Cost-utility analysis of treatment for prevention of osteoporotic fractures
Background: Osteoporosis, a reduction in bone strength, is one of the most significant factors contributing to fractures, particularly in postmenopausal women. It affects not only patients’ life expectancy and quality of life, but also household expenditure on healthcare costs. Various screening methods to identify the risk of developing osteopo
Before Birth, Dad’s ID
t is an uncomfortable question that, in today’s world, is often asked by expectant mothers who had more than one male partner at the time they became pregnant. Who is the father?With more than half of births to women under 30 now out of wedlock, it is a question that may arise more often.Now blood t
Systematic review and meta-analysis of intravitreal bevacizumab (Avastin®) in macular diseases
There is increasing impetus to use pharmaceutical interventions, ie, ranibizumab or bevacizumab, for the treatment of particular macular diseases. This study conducts the evidence synthesis to inform policy decision-making of the National List of Essential Medicines Committee that recently announced the inclusion of bevacizumab for the treatment of
10 / Page